Warning after cancer patients died following delays in getting life-saving emergency drugs
NHS review reveals cause of fatal treatment delays
- At least five cancer patients have died, and three others were admitted to intensive care in the UK after not receiving the emergency medication, rasburicase.
- Rasburicase is vital for treating Tumour Lysis Syndrome (TLS), a serious complication of cancer treatments that can lead to organ damage if untreated.
- An NHS review found that drug shortages and a lack of awareness among doctors about the medication's urgency contributed to these critical delays.
- The review identified 123 safety incidents related to patients not receiving rasburicase, with 14 cases where delays likely led to death or significant health deterioration.
- Hospitals have been instructed to update clinical guidance by March next year, ensure all blood cancer patients receive TLS risk assessments, and maintain sufficient stock of rasburicase.
Bookmark popover
Removed from bookmarks